Rotigotine is safe and efficacious in Atypical Parkinsonism Syndromes induced by both a-synucleinopathy and tauopathy

• Main Authors: Moretti DV, Binetti G, Zanetti O, Frisoni GB
• Format: Article
• Language: English
• Published: Dove Medical Press 2014-06-01
• Series: Neuropsychiatric Disease and Treatment
• Online Access: http://www.dovepress.com/rotigotine-is-safe-and-efficacious-in-atypical-parkinsonism-syndromes--a17123

Davide Vito Moretti, Giuliano Binetti, Orazio Zanetti, Giovanni Battista Frisoni IRCCS San Giovanni di Dio Fatebenefratelli, Brescia, ItalyAbstract: Transdermal rotigotine (RTG) is a non-ergot dopamine agonist (D3>D2>D1), and is indicated for use in early and advanced Parkinson’s disease (PD). RTG patch has many potential advantages due to the immediacy of onset of the therapeutic effect. Of note, intestinal absorption is not necessary and drug delivery is constant, thereby avoiding drug peaks and helping patient compliance. In turn, transdermal RTG seems a suitable candidate in the treatment of atypical Parkinsonian disorders(APS). Fifty-one subjects with a diagnosis of APS were treated with transdermal RTG. The diagnoses were: Parkinson’s disease with dementia, multiple system atrophy Parkinsonian type, multiple system atrophy cerebellar type, progressive supranuclear palsy, corticobasal degeneration, Lewy body dementia, and frontotemporal dementia with Parkinsonism. Patients were evaluated by the Unified Parkinson’s Disease Rating Scale (UPDRS; part III), Neuropsychiatric Inventory (NPI), and mini–mental state examination (MMSE) and all adverse events (AEs) were recorded. Patients treated with RTG showed an overall decrease of UPDRS III scores without increasing behavioral disturbances. Main AEs were hypotension, nausea, vomiting, drowsiness, tachycardia, and dystonia. On the whole, 15 patients were affected by AEs and seven patients suspended RTG treatment due to AEs. The results show that transdermal RTG is effective with a good tolerability profile. RTG patch could be a good therapeutic tool in patients with APS. Keywords: transdermal dopamine agonist, open label study, Parkinson plus